XML 40 R25.htm IDEA: XBRL DOCUMENT
v3.22.0.1

STOCK OPTIONS | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
STOCK OPTIONS | STOCK OPTIONS On October 30, 2007, the Company’s stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the “Plan”) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1.2 million stock options. Stock options to employees typically have a ten-year life and currently vest over periods between one and seven years. In July 2012, the Company’s stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December 31, 2021 approximately 70,000 are available to be issued in this plan. In July 2015, the Company’s stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December 31, 2021 approximately 240,000 are available to be issued in this plan. In August 2017, the Company’s stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December 31, 2021 approximately 80,000 are available to be issued in this plan. In August 2019, the Company’s stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December 31, 2021, all 1,370,000 are available to be issued in this plan. In August 2021, the Company’s stockholders approved the 2021 Share Incentive Plan covering a total of 1,375,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December 31, 2021, all 1,375,000 are available to be issued in this plan. On January 19, 2022, the Company granted employees appro ximately 1,500,000 options to purchase common shares of the Company's stock. All options granted were pursuant to the 2015 and 2019 Plans noted above. The options ves t over a period of three years. The status of the Company’s stock options is summarized as follows:
| Number of options |  | Weighted average exercise price
Outstanding at December 31, 2019 | 3,966,858 |  |  | $ | 4.67 |
Granted | 1,376,900 |  |  | 7.94 |
Exercised | (112,965) |  |  | 3.37 |
Canceled and forfeited | (291,850) |  |  | 7.19 |
Outstanding at December 31, 2020 | 4,938,943 |  |  | $ | 5.46 |
Granted | 894,980 |  |  | 9.37 |
Exercised | (232,521) |  |  | 6.65 |
Canceled and forfeited | (203,711) |  |  | 8.27 |
Outstanding at December 31, 2021 | 5,397,691 |  |  | $ | 5.95 |
| Number of options |  | Weighted average grant date fair value
Non-vested at December 31, 2020 | 2,044,469 |  |  | $ | 4.61 |
Granted | 894,980 |  |  | 5.76 |
Vested | (952,332) |  |  | 4.49 |
Forfeited | (184,901) |  |  | 5.21 |
Non-vested at December 31, 2021 | 1,802,216 |  |  | $ | 5.21 |
Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. Inputs used in the valuation models are as follows:
| 2021 Grants |  | 2020 Grants |  |
Option value | $9.29 | - | $11.51 |  | $4.98 | - | $8.18 |  |  |  |
Risk-free rate | 0.6% | - | 0.8% |  | 0.3% | - | 1.7% |  |  |  |
Expected dividend yield | —% |  | —% |  |
Expected volatility | 68.9% | - | 70.8% |  | 65.9% | - | 70.1% |  |  |  |
Expected term (in years) | 4.5 | - | 6 |  | 6
The Company recognized approximately $5,088,000 and $4,210,000 in stock-based compensation expense during the years ended December 31, 2021 and 2020, respectively. The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2021 is based on the $12.82 closing stock price of the Company's common stock on December 31, 2021, the last trading day of 2021. As of December 31, 2021, there were 5,037,248 stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $35,560,000. These options have a weighted average exercise price of $5.76 and a weighted average remaining contractual term of approximately 6 years. As of December 31, 2021, there were 3,595,475 stock options outstanding and exercisable with an aggregate intrinsic value of approximately $29,460,000. These options have a weighted average exercise price of $4.63 and a weighted average remaining contractual term of approximately 6 years. The total intrinsic value of in the money options exercised during the years ended December 31, 2021 and 2020, was approximately $1,600,000 and $200,000, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. The total fair value of options granted during the years ended December 31, 2021 and 2020, was approximately $5,150,000 and $6,580,000, respectively. The weighted average fair value of options granted during the years ended December 31, 2021 and 2020, was $5.76 and $4.78, respectively. The total fair value of option shares vested during the years ended December 31, 2021 and 2020, was approximately $4,270,000 and $2,510,000, respectively. The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December 31, 2021 and 2020, the Company received 111,831 and 39,448 options as payment in the exercise of 107,357 and 47,088 options, respectively. As of December 31, 2021, there was approximately $5,010,000 of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately 1 year.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration